Navidea Biopharmaceuticals Inc
F:NO1A
Navidea Biopharmaceuticals Inc
F:NO1A
Price:
0.046
EUR
Market Closed
Market Cap:
€4.6m
Balance Sheet
Balance Sheet Decomposition
Navidea Biopharmaceuticals Inc
Navidea Biopharmaceuticals Inc
Balance Sheet Decomposition is not available for
Navidea Biopharmaceuticals Inc
Navidea Biopharmaceuticals Inc
Balance Sheet
Navidea Biopharmaceuticals Inc
Navidea Biopharmaceuticals Inc
Currency: USD
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
33
|
5
|
7
|
2
|
3
|
3
|
1
|
3
|
4
|
2
|
|
| Cash |
33
|
5
|
7
|
2
|
3
|
3
|
1
|
3
|
4
|
2
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
2
|
1
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
1
|
1
|
4
|
0
|
8
|
0
|
1
|
3
|
0
|
0
|
|
| Accounts Receivables |
1
|
1
|
4
|
0
|
8
|
0
|
1
|
3
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
2
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
1
|
1
|
1
|
9
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Total Current Assets |
37
|
9
|
13
|
11
|
14
|
6
|
3
|
7
|
5
|
3
|
|
| PP&E Net |
2
|
3
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
2
|
3
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
1
|
2
|
2
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
5
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
1
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
|
| Total Assets |
40
N/A
|
12
-71%
|
15
+26%
|
12
-17%
|
21
+67%
|
7
-66%
|
4
-41%
|
8
+87%
|
7
-14%
|
4
-34%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
2
|
1
|
2
|
5
|
1
|
0
|
1
|
1
|
1
|
2
|
|
| Accrued Liabilities |
5
|
3
|
3
|
8
|
2
|
3
|
2
|
3
|
3
|
6
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
|
| Current Portion of Long-Term Debt |
4
|
4
|
0
|
52
|
2
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
1
|
5
|
3
|
0
|
0
|
0
|
0
|
1
|
|
| Total Current Liabilities |
11
|
9
|
6
|
70
|
8
|
3
|
4
|
5
|
5
|
10
|
|
| Long-Term Debt |
24
|
29
|
61
|
10
|
0
|
0
|
0
|
0
|
0
|
2
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
0
|
|
| Other Liabilities |
9
|
3
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Total Liabilities |
44
N/A
|
42
-6%
|
69
+66%
|
81
+16%
|
9
-88%
|
5
-44%
|
6
+9%
|
6
+12%
|
7
+5%
|
13
+90%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
317
|
353
|
381
|
395
|
320
|
337
|
348
|
359
|
371
|
388
|
|
| Additional Paid In Capital |
313
|
323
|
326
|
327
|
331
|
338
|
346
|
365
|
370
|
379
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
0
|
0
|
|
| Total Equity |
4
N/A
|
30
-643%
|
54
-82%
|
68
-25%
|
11
N/A
|
2
-85%
|
2
N/A
|
1
N/A
|
0
N/A
|
8
-7 573%
|
|
| Total Liabilities & Equity |
40
N/A
|
12
-71%
|
15
+26%
|
12
-17%
|
21
+67%
|
7
-66%
|
4
-41%
|
8
+87%
|
7
-14%
|
4
-34%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
7
|
8
|
8
|
8
|
8
|
10
|
20
|
27
|
30
|
33
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
